# MMJ ET AL PREPARES APPEAL CMS HEMP PROGRAM: How Can a Company With a … > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/mmj-et-al-prepares-appeal-cms-hemp-program-how-can-a-company-with-a/ > **Published:** 2026-05-30T19:09:55-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T17:00:14-04:00 > **Clinical Summary:** MMJ ET AL appeals CMS cannabis medicine reimbursement restrictions. What this means for patient access and clinical prescribing. --- ✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. PolicyResearchHempCBDSafetyIndustry[Medical Cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) Dr. Caplan’s Take “Until we have FDA-approved cannabis medicines with standardized dosing and demonstrated efficacy in rigorous trials, we’re asking patients to become their own pharmacologists, adjusting dosages and products based on trial and error rather than evidence, which is fundamentally at odds with how we practice medicine in every other domain.” Clinical Perspective The evolving regulatory landscape for cannabis-derived medicines reflects growing recognition that some cannabinoid compounds warrant clinical evaluation through conventional pharmaceutical pathways, though the available summary contains insufficient detail to assess specific claims about FDA approvals or ongoing regulatory proceedings. Clinicians should remain cautious about distinguishing between FDA-approved cannabis-derived pharmaceuticals (currently limited to cannabidiol for specific seizure disorders and [synthetic cannabinoids](https://cedclinic.com/synthetic-cannabinoid-parkinsons-trial-ser-252-funding/) like dronabinol), which have established dosing and safety profiles, and [medical cannabis products](https://cedclinic.com/cannabis-infused-products-skin-diy-topical-recipes/) that remain largely unregulated and poorly characterized in terms of potency, purity, and [drug interactions](https://cedclinic.com/cannabis-liver-interactions-study-insights/). The current gap between emerging basic science suggesting potential therapeutic applications and the rigorous clinical trial data needed to inform practice means that clinicians recommending or discussing cannabis with patients should acknowledge this uncertainty explicitly and document discussions about lack of evidence for most proposed uses. Regulatory appeals and industry advocacy may eventually expand the evidence base for specific [cannabinoid formulations](https://cedclinic.com/brazil-cannabis-regulatory-framework-new-medical-rules/), 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20MMJ%20ET%20AL%20PREPARES%20APPEAL%20CMS%20HEMP%20PROGRAM%3A%20How%20Can%20a%20Company%20With%20a%20...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D56964)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D56964)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20MMJ%20ET%20AL%20PREPARES%20APPEAL%20CMS%20HEMP%20PROGRAM%3A%20How%20Can%20a%20Company%20With%20a%20...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D56964)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://www.newswire.com/news/mmj-et-al-prepares-appeal-cms-hemp-program-how-can-a-company-with-a](https://www.newswire.com/news/mmj-et-al-prepares-appeal-cms-hemp-program-how-can-a-company-with-a) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).